Amalgamated Bank Boosts Stake in Zoetis Inc. $ZTS

Amalgamated Bank raised its position in Zoetis Inc. (NYSE:ZTS) by 2.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 96,278 shares of the company’s stock after buying an additional 1,948 shares during the period. Amalgamated Bank’s holdings in Zoetis were worth $15,015,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Brighton Jones LLC boosted its position in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the last quarter. Mather Group LLC. boosted its position in Zoetis by 4.4% in the 1st quarter. Mather Group LLC. now owns 3,549 shares of the company’s stock valued at $584,000 after buying an additional 151 shares during the last quarter. Pinnacle Financial Partners Inc boosted its position in Zoetis by 0.5% in the 1st quarter. Pinnacle Financial Partners Inc now owns 46,386 shares of the company’s stock valued at $7,637,000 after buying an additional 250 shares during the last quarter. Novem Group lifted its position in shares of Zoetis by 30.8% during the first quarter. Novem Group now owns 6,406 shares of the company’s stock worth $1,055,000 after purchasing an additional 1,507 shares during the last quarter. Finally, Resonant Capital Advisors LLC lifted its position in shares of Zoetis by 7.3% during the first quarter. Resonant Capital Advisors LLC now owns 2,063 shares of the company’s stock worth $340,000 after purchasing an additional 141 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $143.77 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The firm’s 50-day moving average price is $147.40 and its two-hundred day moving average price is $153.41. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $183.11. The stock has a market capitalization of $63.72 billion, a P/E ratio of 24.75, a P/E/G ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter last year, the company posted $1.56 earnings per share. Zoetis’s revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is currently 34.42%.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. UBS Group lowered their price target on Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a report on Monday, October 20th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Finally, Piper Sandler boosted their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average target price of $195.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.